Solid Biosciences Merges with AavantiBio
The combined company will focus on the advancement of neuromuscular and cardiac programs for the treatment of Duchenne muscular dystrophy.
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
